Claims for Patent: RE43431

Summary for Patent: RE43431

Title:	Quinazoline derivatives and pharmaceutical compositions containing them
Abstract:	A compound of general formula I ##STR00001## wherein: R.sub.a is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; R.sub.b is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and R.sub.c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.
Inventor(s):	Himmelsbach; Frank (Mittelbiberach, DE), Langkopf; Elke (Biberach an der Riss, DE), Blech; Stefan (Warthausen, DE), Jung; Birgit (Laupheim, DE), Baum; Anke (Vienna, AT), Solca; Flavio (Vienna, AT)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:	12/542,929
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE43431
Patent Claims:	1. A compound of formula I ##STR00006## wherein R.sub.a is a .[.benzyl, 1-phenylethyl, or.]. 3-chloro-4-fluorophenyl group; R.sub.b is a dimethylamino.[., N-methyl-N-ethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino.]. group; and R.sub.c is a .[.cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy,.]. tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a stereoisomer or physiologically acceptable salt thereof. .[.2. The compound of claim 1, wherein Rb is a dimethylamino or a stereoisomer or physiologically acceptable salt thereof..]. .[.3. The compound of formula I according to claim 1, wherein: R.sub.a is a 1-phenylethyl or 3-chloro-4-fluorophenyl group; R.sub.b is a dimethylamino, N-methyl-N-ethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and R.sub.c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetradrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a stereoisomer or physiologically acceptable salt thereof..]. .[.4. The compounds of claim 3, wherein R.sub.b is a dimethylamino, or a stereoisomer or physiologically acceptable salt thereof..]. .[.5. The compounds of claim 3, wherein R.sub.a is a 3-chloro-4-fluorohenyl group and R.sub.b is a dimethylamino group, or a stereoisomer or physiologically acceptable salt thereof..]. .[.6. The compound of formula I according to claim 1, wherein: R.sub.a is a 3-chloro-4-fluorophenyl group; R.sub.b is a dimethylaminno group; and R.sub.c is a tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a steroisomer or physiologically acceptable salt thereof..]. .Iadd.7. The compound of claim 1, wherein: R.sub.c is a tetrahydrofuran-3-yloxy, or a steroisomer or physiologically acceptable salt thereof..Iaddend. .Iadd.8. 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-o- xo-2-buten-1-yl]amino}-7-((S)-(tetrahydrofuran-3-yl)oxy)quinazoline..Iadde- nd. .Iadd.9. A physiologically acceptable salt comprising the combination of the compound according to claim 8 with an organic or inorganic acid..Iaddend. .Iadd.10. The salt according to claim 9 wherein the acid is hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid..Iaddend. .Iadd.11. The salt according to claim 10, wherein the acid is maleic acid..Iaddend. .Iadd.12. 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-- oxo-2-buten-1-yl]amino}-7-((R)-(tetrahydrofuran-3-yl)oxy)quinazoline..Iadd- end.